Publications by authors named "Jesus Acosta"

Claim this Profile
M
Management of invasive cervical carcinoma in three oncology centers in Latin America: A historical cohort study.
Jonathan Peralta, Juliana Rodriguez, Jesús Antonio Acosta, Marcela Nuñez, Lina Buitrago

Int J Gynaecol Obstet· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Eric S Christenson, Won Jin Ho, Daniel Shu, Jennifer N Durham, Madelena Brancati, Ana de Jesus-Acosta

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feeding a nutrient enriched diet to late gestating sows across consecutive cycles improves micronutrient status, farrowing duration, and prolificacy.
Katlyn A McClellan, Jesus Acosta, Brad Lawrence, Sara Hough, Jon Bergstrom

Transl Anim Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Eric S Christenson, Won Jin Ho, Daniel Shu, Jennifer N Durham, Madelena Brancati, Ana de Jesus-Acosta

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving Immunotherapy Strategies in Gastrointestinal Neuroendocrine Neoplasms.
Arielle Urman, Ian Schonman, Ana De Jesus-Acosta

Curr Treat Options Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Aurelien Marabelle, David M O'Malley, Andrew E Hendifar, Paolo A Ascierto, Daniel Motola-Kuba, Ana De Jesus-Acosta

Nat Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma.
Chirayu Mohindroo, Paul S Dy, Suraj P Hande, Christopher R D'Adamo, Arun Mavanur, Ana De Jesus-Acosta

J Gastrointest Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Approach in the Interpretation of Complex Triple-negative Breast Cancer Immunohistochemistry Specimens Processed With VENTANA PD-L1 (SP142) Assay.
Vicente Peg, Marta Abengozar-Muela, Jesús Acosta, Leire Andrés, Marcial García-Rojo

Appl Immunohistochem Mol Morphol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.
Amol Gupta, Ana De Jesus-Acosta, Dung Le, Michael Pishvaian, Neeha Zaidi

Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After Lu-DOTATATE Therapy.
Andrew F Voter, Andrei Gafita, Rudolf A Werner, Ana De Jesus-Acosta, Steven P Rowe

J Nucl Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.
Ana De Jesus-Acosta, Chirayu Mohindroo

JCO Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.
Chirayu Mohindroo, Seyda Baydogan, Parul Agarwal, Robin D Wright, Laura R Prakash, Ana De Jesus-Acosta

Cancer Prev Res (Phila)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial design of the MOTheR HDx study: a multicenter, open-label, prospective, randomized study to explore the morbidity and mortality in patients dialyzed with the Theranova HDx in comparison with online hemodiafiltration.
Patricia de Sequera, Rafael Pérez-García, Almudena Vega, Shaira Martínez-Vaquera, Jesús Guillermo Acosta

Clin Kidney J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The STOP Program: a Hybrid Smoking Prevention and Cessation Training for Cancer Care Providers in Colombia and Peru.
Irene Tamí-Maury, Samuel Tundealao, Vilma Díaz, Elizabeth Ochoa, Esperanza Garcia, Jesús Acosta

J Cancer Educ· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer.
H Catherine Wilbur, Jennifer N Durham, Su Jin Lim, Katrina Purtell, Katherine M Bever, Ana De Jesus-Acosta

Cancer Res Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
Amol Gupta, Ana De Jesus-Acosta, Lei Zheng, Valerie Lee, Ihab Kamel

Front Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma.
Thatcher Heumann, Carol Judkins, Keyu Li, Su Jin Lim, Jessica Hoare, Ana De Jesus-Acosta

Nat Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solid Organ Transplantation Is Associated with an Increased Rate of Mismatch Repair Deficiency and PIK3CA Mutations in Colorectal Cancer.
Eric S Christenson, Valerie Lee, Hao Wang, Mark Yarchoan, Ana De Jesus-Acosta

Curr Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.
Eric S Christenson, Su Jin Lim, Jennifer Durham, Ana De Jesus-Acosta, Katherine Bever

Cancer Res Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetics of Pancreatic Neuroendocrine Tumors.
Chirayu Mohindroo, Florencia McAllister, Ana De Jesus-Acosta

Hematol Oncol Clin North Am· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
M Maio, P A Ascierto, L Manzyuk, D Motola-Kuba, N Penel, A De Jesus Acosta

Ann Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.
Chirayu Mohindroo, Ana De Jesus-Acosta, Matthew B Yurgelun, Anirban Maitra, Maureen Mork

Surg Pathol Clin· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study.
D M O'Malley, G M Bariani, P A Cassier, A Marabelle, A R Hansen, A De Jesus Acosta

Gynecol Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
Fanfan Xie, Ding Ding, Cong Lin, Dea Cunningham, Michael Wright, Ana De Jesus-Acosta

JCO Precis Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
Abhinav V Reddy, Colin S Hill, Shuchi Sehgal, Lei Zheng, Jin He, Ana De Jesus-Acosta

Radiat Oncol J· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis